A 15-ketosterol is a liver X receptor ligand that suppresses sterol-responsive element binding protein-2 activity

Autor: Schmidt, Robert J. ^*, Ficorilli, James V. ^*, Zhang, Youyan ^*, Bramlett, Kelli S. ^*, Beyer, Thomas P. ^*, Borchert, Kristen ^*, Dowless, Michele S. ^*, Houck, Keith A. ^*, Burris, Thomas P. ^*, Eacho, Patrick I. ^*, Liang, Guosheng ^*, Guo, Li-wei, Wilson, William K., Michael, Laura F. ^*, Cao, Guoqing ^*

Publikováno v: In Journal of Lipid Research May 2006 47(5):1037-1044

Cyclic AMP-independent activation of CYP3A4 gene expression by forskolin

Autor: Dowless, Michele S., Barbee, James L., Borchert, Kristen M., Bocchinfuso, Wayne P., Houck, Keith A.

Publikováno v: In European Journal of Pharmacology 2005 512(1):9-13

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Imlunestrant is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wildtype and Mutant Breast Cancer.

Autor: Bhagwat SV; Eli Lilly and Company, Indianapolis, Indiana, United States., Mur C; Eli Lilly and Company, Madrid, Spain., Vandekopple M; Eli Lilly and Company, Indianapolis, IN, United States., Zhao B; Eli Lilly and Company, Indianapolis, IN, United States., Shen W; Eli Lilly and Company, Indianapolis, Indiana, United States., Marugán C; Eli Lilly (Spain), Alcobendas, Madrid, Spain., Capen A; Eli Lilly and Company, Indianapolis, IN, United States., Kindler L; Eli Lilly and Company, Indianapolis, IN, United States., Stephens JR; Eli Lilly and Company, Indianapolis, Indiana, United States., Huber L; Eli Lilly and Company, Indianapolis, IN, United States., Castanares MA; Eli Lilly and Company, Indianapolis, IN, United States., Garcia-Tapia D; Eli Lilly and Company, Indianapolis, IN, United States., Cohen JD; Eli Lilly and Company, Indianapolis, IN, United States., Bastian J; Eli Lilly and Company, Indianapolis, IN, United States., Mattioni B; Eli Lilly and Company, Indianapolis, IN, United States., Yuen E; Eli Lilly and Company, United States., Baker TK; Eli Lilly and Company, United States., Rodriguez Cruz V; Eli Lilly and Company, United States., Fei D; Eli Lilly and Company, United States., Manro JR; Eli Lilly and Company, Indianapolis, IN, United States., Pulliam N; Eli Lilly and Company, Indianapolis, IN, United States., Dowless MS; Eli Lilly and Company, Indianapolis, Indiana, United States., Ortiz Ruiz MJ; Eli Lilly and Company, Madrid, Spain., Yu C; Lilly (China), Shanghai, Shanghai, China., Puca L; Eli Lilly (United States), New York, New York, United States., Klippel A; Eli Lilly and Company, New York City, New York, United States., Bacchion F; Eli Lilly and Company, Indianapolis, IN, United States., Ismail-Khan R; Eli Lilly and Company, Indianapolis, IN, United States., Rodrik-Outmezguine V; Eli Lilly and Company, Indianapolis, IN, United States., Peng SB; Eli Lilly and Company, Indianapolis, IN, United States., Lallena MJ; Eli Lilly and Company, Madrid, Spain., Gong X; Eli Lilly and Company, Indianapolis, Indiana, United States., de Dios A; Eli Lilly (United States), Indianapolis, United States.

Publikováno v: Cancer research [Cancer Res] 2024 Dec 09. Date of Electronic Publication: 2024 Dec 09.